LITTLE ROCK, ., Sep 10, 2014 (BUSINESS WIRE) -- Cantrell Drug Company today announced it has entered into an exclusive agreement to become the first human drug compounding outsourcing facility to utilize Aseptic Technologies’ closed vial system for aseptic filling of injectable drugs. Outsourcing facilities were created under the federal Drug Quality and Security Act (DQSA) enacted in November 2013.
Under the agreement, Cantrell Drug Company will prepare sterile compounded medications with Aseptic Technologies’ Crystal® Closed Vial Technology, which was designed to increase patient safety by vastly reducing the risk of contamination during the complex filling process used by sterile compounding pharmacies and outsourcing facilities. The new technology simplifies and reduces the risk associated with the glass vial filling process used by pharmaceutical manufacturers. Additionally, it provides easier handling for pharmacists and hospital staff who dispense medication.
http://www.marketwatch.com/story/cantrell-drug-company-enhances-compounding-safety-with-closed-vial-filling-system-from-aseptic-technologies-2014-09-10
Under the agreement, Cantrell Drug Company will prepare sterile compounded medications with Aseptic Technologies’ Crystal® Closed Vial Technology, which was designed to increase patient safety by vastly reducing the risk of contamination during the complex filling process used by sterile compounding pharmacies and outsourcing facilities. The new technology simplifies and reduces the risk associated with the glass vial filling process used by pharmaceutical manufacturers. Additionally, it provides easier handling for pharmacists and hospital staff who dispense medication.
http://www.marketwatch.com/story/cantrell-drug-company-enhances-compounding-safety-with-closed-vial-filling-system-from-aseptic-technologies-2014-09-10
No comments:
Post a Comment